Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy

New York Blood Center Enterprises (NYBCe), a leader in blood and transfusion medicine for more than 60 years, advances cell and gene therapy through Comprehensive Cell Solutions (CCS), a mission-driven CDMO delivering integrated Draw-to-Thaw™ capabilities. CCS connects donor sourcing, process and analytical development, GMP manufacturing, and cryogenic storage within a unified quality system designed to streamline development and accelerate clinical readiness.

In this live capacity update, CCS will highlight current open GMP manufacturing availability at its Rye, New York headquarters, where the full Draw-to-Thaw™ model operates under one roof. The Rye campus uniquely integrates a dedicated on-site donor center and apheresis facility with GTP labs and GMP cleanroom suites, a centralized Cryopreservation Center of Excellence, and vapor-phase liquid nitrogen storage farm. This co-located infrastructure reduces handoffs, strengthens chain of identity and chain of custody controls, and minimizes logistical risk from starting material collection through final cryopreserved product.

CCS supports cellular therapies across multiple modalities, including minimally manipulated and expanded cell platforms, in both autologous and allogeneic settings. With capabilities spanning development through GMP manufacturing and storage, CCS provides the operational depth and available capacity sponsors need to advance programs efficiently and reliably.

Join us to learn how CCS’s integrated Draw-to-Thaw™ infrastructure and open GMP suites in Rye can support your next clinical milestone.